News Category
GeoVax's next-generation MVA-X vaccine demonstrated durable single-dose protection against lethal Clade I mpox and other orthopoxviruses, potentially ...
Onco-Innovations is advancing its lead preclinical cancer candidate ONC010 toward first-in-human testing by aligning manufacturing, formulation, and r...
Experts emphasize that asking about clinical trials at the first appointment can open doors to promising new treatments and improved quality of life f...
Telomir Pharmaceuticals reports that its lead candidate Telomir-Zn inhibited growth in human and canine osteosarcoma cell lines, supporting further tr...
Dr. Wael Sakr has announced a one-time $1,000 scholarship for undergraduate pre-med students, aiming to reduce financial barriers and encourage divers...
Creative Biolabs has upgraded its single-cell and single-nucleus RNA sequencing and multi-omics services to help researchers overcome sample processin...
A comprehensive review reveals that the tumor microenvironment actively sculpts natural killer cells into distinct functional subsets, offering new av...
The September 17 Life Sciences Virtual Investor Forum will feature live presentations and Q&A from seven companies developing therapies in oncology, f...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer signals a strategic push to advance its BiTAC® T-cell engager technolo...
Quantum BioPharma's Lucid-MS has received FDA clearance to begin a Phase 2 trial in multiple sclerosis, potentially offering a novel approach that tar...
Onco-Innovations' CMO discusses the company's lead drug candidate ONC010, which targets the DNA repair enzyme PNKP with a dual selectivity approach, a...
Quantum BioPharma's FDA clearance for its Lucid-MS Investigational New Drug application marks a pivotal step toward a Phase 2 trial, potentially offer...
Kairos Pharma's CEO presentation at a major investment conference underscores the company's progress in developing ENV-105, a promising therapy aimed ...
GeoVax supports the new global mpox vaccine stockpile and emphasizes its GEO-MVA candidate's potential to diversify supply and enhance preparedness.
VERAXA Biotech's appointment of Raju Willener as CFO signals a strategic move to bolster its financial leadership and advance its proprietary BiTAC te...
Onco-Innovations Ltd. strengthens its clinical foundation through manufacturing milestones, IND-enabling activities, and funding, positioning its PNKP...
Researchers at Washington University School of Medicine have advanced laser interstitial thermal therapy (LITT) as a less invasive brain cancer treatm...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in a Phase 2 trial marks a potential breakthrough in treatin...
OS Animal Health, a subsidiary of OS Therapies, is spotlighted at the Moody Capital conference for its promising OST-HER2 immunotherapy targeting cani...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in a phase 2 trial could herald a new era in MS therapy, add...
NanoViricides has registered its Phase II trial for NV-387 Oral Gummies against Ebola in the Pan African Clinical Trials Registry, marking a critical ...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial could revolutionize MS therapy by targeting demyelination rather than immunosuppression, ...
Recent data shows historic lows in youth tobacco use, but adult smoking remains a public health crisis, prompting FDA authorization of ZYN nicotine po...
A large study reveals that the timing of brain metastasis development significantly impacts survival in colorectal cancer patients, highlighting the n...
VERAXA Biotech's appointment of seasoned financial leader Raju Willener as CFO signals a strategic move to strengthen capital markets expertise and su...
Onco-Innovations has made significant preclinical progress on its PNKP inhibitor ONC010, including high-purity API production and a planned Australian...
OS Therapies' participation in the Moody Capital conference comes as the company anticipates key regulatory decisions and data readouts for its lead c...
A Swiss-led preclinical study reveals that administering immunotherapy before surgery significantly improves glioblastoma treatment outcomes, potentia...
New research reveals that unintended radiation to the thymus during lung cancer treatment is associated with poorer survival, highlighting the need to...
Dr. Salman Fazal, a hematologist and stem cell transplant expert at UPMC Hillman Cancer Center, has been named a Castle Connolly Top Doctor for 2026, ...
NanoViricides is progressing its measles drug candidate NV-387 toward Phase II trials, leveraging FDA designations and promising preclinical data, as ...
TransCode Therapeutics announced preclinical results showing TTX-MC138 improves survival in a breast cancer bone metastasis model, supporting its RNA-...
A nurse's personal battle with metastatic triple-negative breast cancer underscores the critical need for awareness of innovative treatments like anti...
An expert and a patient explain why PSMA PET imaging is crucial for determining prostate cancer spread and guiding treatment, urging men to discuss it...
The NMPA's approval of a Phase Ib/II trial for HDP-101 combinations in China marks a significant step in expanding the ADC's potential across earlier ...
A new study published in Critical Care Medicine reveals VolitionRx's Nu.Q NETs H3.1 biomarker independently predicts 28-day mortality and renal replac...
Novogenia AG's U.S. launch of the MGT Plus methylation test, which analyzes 27 genes across six pathways, expands its partnership with 10X Health and ...
Citius Pharmaceuticals leverages FDA-approved LYMPHIR's commercial launch and a promising late-stage pipeline to address unmet medical needs and drive...
Annovis Bio will provide updates on its Phase 3 Alzheimer's trial and other clinical programs, highlighting upcoming milestones that could significant...
A new study indicates that a personalized mRNA vaccine can prevent melanoma recurrence for years, marking a significant advancement in cancer treatmen...
Dr. David Zelby, a Marietta prosthodontist with over 40 years of experience, has been named a 2026 Castle Connolly Top Dentist, an honor awarded to on...
Creative Biolabs announces a webinar on modeling T cell dysfunction in tumor microenvironments, highlighting the role of metabolic stress in immune ev...
A novel T cell therapy offers new hope for patients with recurrent glioblastoma, a condition with limited treatment options and poor prognosis.
VERAXA Biotech and Secarna's early in vitro results show their AOC candidate is more potent than unconjugated oligonucleotides, validating the approac...
VERAXA Biotech's VXA-222 bispecific antibody-drug conjugate program has moved into preclinical development, marking a key milestone and strengthening ...
The Keith Dagostino Scholarship for Cancer Survivors opens applications, offering financial aid to undergraduate cancer survivors nationwide, emphasiz...
VERAXA Biotech's favorable Scientific Advice from Germany's Paul-Ehrlich-Institute de-risks its lead BiTAC-TCE therapy, underscoring the importance of...
VERAXA Biotech's proprietary BiTAC platform and recent pipeline advances underscore its commitment to precision oncology, with potential implications ...
